Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment

P. J. Niziolek, S. Murthy, S. N. Ellis, K. B. Sukhija, T. A. Hornberger, C. H. Turner, Alexander Robling

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The osteo-anabolic effects of intermittent parathyroid hormone (PTH) treatment require insulin-like growth factor (IGF) signaling through the IGF-I receptor. A major downstream target of the IGF-I receptor (via Akt) is the mammalian target of rapamycin (mTOR), a kinase involved in protein synthesis. We investigated whether the bone-building effects of intermittent PTH require functional mTOR signaling. Mice were treated with daily PTH 1-34 (0, 10, 30, or 90 μg/kg) for 6 weeks in the presence or absence of rapamycin, a selective inhibitor of mTOR. We found that all PTH doses were effective in enhancing bone mass, whether rapamycin was present or not. Rapamycin had little to no effect on the anabolic response at low (10 μg) PTH doses, small effects in a minority of anabolic measures at moderate doses (30 μg), but the anabolic effects of high-dose PTH (90 μg) were consistently and significantly suppressed by rapamycin (∼4-36% reduction). Serum levels of Trap5b, a marker of resorption, were significantly enhanced by rapamycin, but these effects were observed whether PTH was absent or present. Our data suggest that intermittent PTH, particularly at lower doses, is effective in building bone mass in the presence of rapamycin. However, the full anabolic effects of higher doses of PTH are significantly suppressed by rapamycin, suggesting that PTH might normally activate additional pathways (including mTOR) for its enhanced high-dose anabolic effects. Clinical doses of intermittent PTH could be an effective treatment for maintaining or increasing bone mass among patients taking rapamycin analogs for unrelated health issues.

Original languageEnglish
Pages (from-to)579-585
Number of pages7
JournalJournal of Cellular Physiology
Volume221
Issue number3
DOIs
StatePublished - Dec 2009

Fingerprint

Sirolimus
Parathyroid Hormone
Bone
Anabolic Agents
Bone and Bones
IGF Type 1 Receptor
Cancellous Bone
Somatomedins
Phosphotransferases
Health

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. / Niziolek, P. J.; Murthy, S.; Ellis, S. N.; Sukhija, K. B.; Hornberger, T. A.; Turner, C. H.; Robling, Alexander.

In: Journal of Cellular Physiology, Vol. 221, No. 3, 12.2009, p. 579-585.

Research output: Contribution to journalArticle

Niziolek, P. J. ; Murthy, S. ; Ellis, S. N. ; Sukhija, K. B. ; Hornberger, T. A. ; Turner, C. H. ; Robling, Alexander. / Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. In: Journal of Cellular Physiology. 2009 ; Vol. 221, No. 3. pp. 579-585.
@article{b0e9140a9e03408bac6dafdb43b9fbad,
title = "Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment",
abstract = "The osteo-anabolic effects of intermittent parathyroid hormone (PTH) treatment require insulin-like growth factor (IGF) signaling through the IGF-I receptor. A major downstream target of the IGF-I receptor (via Akt) is the mammalian target of rapamycin (mTOR), a kinase involved in protein synthesis. We investigated whether the bone-building effects of intermittent PTH require functional mTOR signaling. Mice were treated with daily PTH 1-34 (0, 10, 30, or 90 μg/kg) for 6 weeks in the presence or absence of rapamycin, a selective inhibitor of mTOR. We found that all PTH doses were effective in enhancing bone mass, whether rapamycin was present or not. Rapamycin had little to no effect on the anabolic response at low (10 μg) PTH doses, small effects in a minority of anabolic measures at moderate doses (30 μg), but the anabolic effects of high-dose PTH (90 μg) were consistently and significantly suppressed by rapamycin (∼4-36{\%} reduction). Serum levels of Trap5b, a marker of resorption, were significantly enhanced by rapamycin, but these effects were observed whether PTH was absent or present. Our data suggest that intermittent PTH, particularly at lower doses, is effective in building bone mass in the presence of rapamycin. However, the full anabolic effects of higher doses of PTH are significantly suppressed by rapamycin, suggesting that PTH might normally activate additional pathways (including mTOR) for its enhanced high-dose anabolic effects. Clinical doses of intermittent PTH could be an effective treatment for maintaining or increasing bone mass among patients taking rapamycin analogs for unrelated health issues.",
author = "Niziolek, {P. J.} and S. Murthy and Ellis, {S. N.} and Sukhija, {K. B.} and Hornberger, {T. A.} and Turner, {C. H.} and Alexander Robling",
year = "2009",
month = "12",
doi = "10.1002/jcp.21887",
language = "English",
volume = "221",
pages = "579--585",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment

AU - Niziolek, P. J.

AU - Murthy, S.

AU - Ellis, S. N.

AU - Sukhija, K. B.

AU - Hornberger, T. A.

AU - Turner, C. H.

AU - Robling, Alexander

PY - 2009/12

Y1 - 2009/12

N2 - The osteo-anabolic effects of intermittent parathyroid hormone (PTH) treatment require insulin-like growth factor (IGF) signaling through the IGF-I receptor. A major downstream target of the IGF-I receptor (via Akt) is the mammalian target of rapamycin (mTOR), a kinase involved in protein synthesis. We investigated whether the bone-building effects of intermittent PTH require functional mTOR signaling. Mice were treated with daily PTH 1-34 (0, 10, 30, or 90 μg/kg) for 6 weeks in the presence or absence of rapamycin, a selective inhibitor of mTOR. We found that all PTH doses were effective in enhancing bone mass, whether rapamycin was present or not. Rapamycin had little to no effect on the anabolic response at low (10 μg) PTH doses, small effects in a minority of anabolic measures at moderate doses (30 μg), but the anabolic effects of high-dose PTH (90 μg) were consistently and significantly suppressed by rapamycin (∼4-36% reduction). Serum levels of Trap5b, a marker of resorption, were significantly enhanced by rapamycin, but these effects were observed whether PTH was absent or present. Our data suggest that intermittent PTH, particularly at lower doses, is effective in building bone mass in the presence of rapamycin. However, the full anabolic effects of higher doses of PTH are significantly suppressed by rapamycin, suggesting that PTH might normally activate additional pathways (including mTOR) for its enhanced high-dose anabolic effects. Clinical doses of intermittent PTH could be an effective treatment for maintaining or increasing bone mass among patients taking rapamycin analogs for unrelated health issues.

AB - The osteo-anabolic effects of intermittent parathyroid hormone (PTH) treatment require insulin-like growth factor (IGF) signaling through the IGF-I receptor. A major downstream target of the IGF-I receptor (via Akt) is the mammalian target of rapamycin (mTOR), a kinase involved in protein synthesis. We investigated whether the bone-building effects of intermittent PTH require functional mTOR signaling. Mice were treated with daily PTH 1-34 (0, 10, 30, or 90 μg/kg) for 6 weeks in the presence or absence of rapamycin, a selective inhibitor of mTOR. We found that all PTH doses were effective in enhancing bone mass, whether rapamycin was present or not. Rapamycin had little to no effect on the anabolic response at low (10 μg) PTH doses, small effects in a minority of anabolic measures at moderate doses (30 μg), but the anabolic effects of high-dose PTH (90 μg) were consistently and significantly suppressed by rapamycin (∼4-36% reduction). Serum levels of Trap5b, a marker of resorption, were significantly enhanced by rapamycin, but these effects were observed whether PTH was absent or present. Our data suggest that intermittent PTH, particularly at lower doses, is effective in building bone mass in the presence of rapamycin. However, the full anabolic effects of higher doses of PTH are significantly suppressed by rapamycin, suggesting that PTH might normally activate additional pathways (including mTOR) for its enhanced high-dose anabolic effects. Clinical doses of intermittent PTH could be an effective treatment for maintaining or increasing bone mass among patients taking rapamycin analogs for unrelated health issues.

UR - http://www.scopus.com/inward/record.url?scp=70449698050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449698050&partnerID=8YFLogxK

U2 - 10.1002/jcp.21887

DO - 10.1002/jcp.21887

M3 - Article

C2 - 19639601

AN - SCOPUS:70449698050

VL - 221

SP - 579

EP - 585

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 3

ER -